Company Overview
About Enterprise Therapeutics
Enterprise Therapeutics is a British biotechnology company founded in 2012 and headquartered in Brighton, United Kingdom, focused on discovering and developing small-molecule drugs that target ion channels and mucus secretion biology in the airways. The company's scientific foundation draws on the biology of chloride and calcium-activated channels — particularly the TMEM16A chloride channel — which regulate mucus production and hydration in the lungs. Dysfunctional mucus clearance is a common pathological feature of cystic fibrosis (CF), chronic obstructive pulmonary disease (COPD), and non-CF bronchiectasis, conditions that collectively affect tens of millions of patients globally. By modulating these channels with small molecules, Enterprise Therapeutics aims to develop treatments that restore airway surface liquid and improve mucociliary clearance independent of the genetic mutation driving the disease.
Business Model & Competitive Advantage
Enterprise Therapeutics has raised more than £50M from investors led by Syncona, a London-listed life sciences investment company, alongside other specialist healthcare investors. The company's lead program, ETD002, is a TMEM16A potentiator designed to increase chloride secretion and thin mucus in CF patients who do not respond to or are ineligible for CFTR modulators like Vertex's Trikafta. ETD002 has advanced into clinical development, positioning Enterprise Therapeutics as a rare pure-play ion channel company with a clinical-stage respiratory asset. The company's pipeline also includes compounds targeting mucin hypersecretion and inflammation.
Competitive Landscape 2025–2026
Enterprise Therapeutics competes in the respiratory drug discovery space alongside programs from AstraZeneca, Novartis, and academic spinouts from the Wellcome Sanger Institute and University of California San Francisco. Its focus on ion channel biology as a route to mucus normalization — rather than the gene-correction approach of CFTR modulators — gives it scientific and commercial differentiation, particularly for the large population of CF patients with mutations not addressed by existing modulator therapies, as well as the broader COPD and bronchiectasis markets where no disease-modifying therapies currently exist.
Frequently Asked Questions
Similar Brands
Pliant Therapeutics
Pliant Therapeutics develops small molecule integrin inhibitors targeting the pathological tissue scarring (fibrosis) that drives diseases including idiopathic pulmonary fibrosis (IPF), primary sclero
BioNTech
BioNTech SE was founded in 2008 in Mainz, Germany by Ugur Sahin, Ozlem Tureci, and Christoph Huber with a mission to harness the immune system for individualized cancer treatment. The company pioneere
Genentech
Genentech was founded in 1976 in South San Francisco by Herbert Boyer and Robert Swanson, becoming the first company to produce human insulin using recombinant DNA technology and essentially launching
Illumina
Illumina was founded in 1998 in San Diego and has grown into the undisputed leader in next-generation sequencing (NGS), with approximately 80% global market share across research and clinical applicat
Regeneron
Regeneron Pharmaceuticals was founded in 1988 in Tarrytown, New York by Leonard Schleifer and George Yancopoulos. The company built its reputation on the Velocimmune platform—a proprietary humanized m
Vivtex
Vivtex is an MIT Langer Laboratory spinout that has developed a drug delivery platform enabling oral administration of biologics — proteins, peptides, and other large molecules — that have historicall
Compare Enterprise Therapeutics with Competitors
Side-by-side AI visibility scores, platform breakdown, and market position.
Claim This Profile
Are you from Enterprise Therapeutics? Claim your profile to see full AI mention excerpts, get weekly visibility change alerts, and optimize how AI systems describe your brand.
Claim Enterprise Therapeutics Profile →Track AI Visibility in Real Time
Monitor how ChatGPT, Gemini, Perplexity, and Claude mention Enterprise Therapeutics vs competitors. Get alerts when AI recommendations shift.
Start Free Tracking →